In vitro, in various experimental cell models of cervical cancer, SEMA4C was able to potentiate tumor lymphangiogenesis and lymphatic metastasis [99], modulate TGFβ-mediated EMT [100] and promote EMT-mediated cisplatin resistance [101]. The gene discussed is TGFB1; the disease is cervical cancer.